News

Like the entirety of the world, the COVID-19 pandemic exposed many issues in the medical industry. One area in particular: the clinical trials space developed many challenges as a result to the height and continuous battle of the pandemic.

The interplay between nonalcoholic fatty liver disease and diabetes can amplify both conditions, say two prominent researchers.

The setback for GlaxoSmithKline comes amid a multicompany race to develop a vaccine against respiratory syncytial virus infections.

Based on several reports in the last couple of years, it’s been a standout that healthcare consumers’ engagement in their own healthcare will drive better outcomes and reduce care costs. With that being said, consumer experience has come under major focus across the industry as a key business driver.

One of the priorities of the new institute at Virginia Commonwealth University’s medical school will be research into nonalcoholic steatohepatitis (NASH) as a key component in the emerging construct of metabolic health, says its leader, Arun J. Sanyal, M.D.

FDA approved Legend Biotech’s chimeric antigen receptor T-cell (CAR-T) treatment, Carvykti (ciltacabtagene autoleucel; cilta- cel), to treat relapsed or refractory multiple myeloma (RRMM) who have received four or more prior lines of therapy.

Briana Contreras, editor of Managed Healthcare Executive spoke with Jason Warrelmann, global director of Healthcare and Life Sciences at UiPath, in this week's episode of Tuning In to the C-Suite podcast. In the discussion Jason addressed the incline of automation in healthcare, why it's necessary for patients and providers and how other healthcare organizations can better overcome the challenges of adopting automation within their health system.

Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.

Guidelines tell prescribers and patients to avoid switching among levothyroxine products from different manufacturers. But Mayo Clinc-led research finds little difference between switchers and nonswitchers.

CDC figures from June 2020 show that about 41% of adults had opted to delay visiting a medical provider. Now, 20-plus months later, care avoidance of common chronic and acute conditions has only worsened.

Ideally, value-based and technology programs combine to produce better outcomes. But researchers at University of California, San Francisco, found little evidence of synergy in the meaningful use, patient-centered medical home and Medicare Shared Savings Program ACO program.

The new indication for reducing the risk of cardiovascular death and hospitalization for heart failure is expected to boost Jardiance’s sales further. Revenue for the drug jumped 38% in 2021 to reach nearly $432 million globally.

Colorectal cancer disparities between Black and white adults were eliminated among Kaiser Permanente members in Northern California after the healthcare organization instituted a regionwide, structured colorectal cancer screening program.

In this first part of a two-part video series, Wes Gilson, senior director MR of Business Development at Siemens Healthineers, addresses why improving access to magnetic resonance imaging (MRI) is crucial to advancing health equity, and what barriers are limiting that access to patients.

This guidance discusses that individuals 12 years and older can receive the second dose of the Pfizer-BioNTech vaccine 3-8 weeks after the first. Additionally, the interval for those 18 years and older for Moderna is 4-8 weeks.

A recent study found 70% of patients believe remote patient monitoring enables better care management.

In discussing company’s drug spend report, CVS Caremark President Alan Lotvin, M.D., bats away criticism of the pharmacy benefits management (PBM) industry, blames drugmakers for high drug prices, and says independent pharmacies are doing well because of participation in “humongous buying groups.”

Most Health plans and much of healthcare, overall, have had their feet on the gas when it comes to more patient-centered care or consumer choice services. COVID-19 has clearly made it all about the consumer in many ways, but more specifically, in making care much more accessible.

Sanofi and GSK today announce will try to get approval from the FDA and the European Medicines Agency (EMA) for their COVID-19 vaccine, entering a crowded market.

With the COVID-19 pandemic ongoing and alarming levels of healthcare workers still experiencing stress, burnout, and other negative feelings surrounding their work, it's time to return the favors they've given countless others.

During the state of the industry webinar, AHIP experts reviewed policies and solutions to improve affordable access to care and shape healthcare in the post-pandemic world.

EmsanaRx, a pharmacy benefit manager launched by the Purchaser Business Group on Health, started operations in January.

The FDA’s authorization would depend on ongoing studies establishing that a fourth dose would shore up people’s molecular defenses that waned after their first booster shot.

New report includes research findings on insulin biosimilars use among retail pharmacists and physicians.

The CDC released the first real world data February 15 in a Morbidity and Mortality Weekly Report (MMWR) that infants younger than 6 months were overall 61% less likely to be hospitalized from COVID-19 if their mothers were vaccinated during pregnancy through completion of a 2-dose primary mRNA COVID-19 vaccine series with either Pfizer-BioNTech (Comirnaty) or Moderna (Spikevax).

A look at the challenges hospitals face due to an insufficient supply chain—and how to address them.

A vast majority said they plan to continue using telemedicine even beyond the pandemic, according to a report from Doximity.

There have been an alarming increase of ransomware attacks on healthcare systems in 2021—with more than 65 reported ransomware attacks on healthcare organizations in the third quarter alone and two-thirds of organization reporting that they had been targeted by ransomware strikes—a trend that is likely to continue in 2022.